Second draft of 21st Century Cures released

The U.S. House Energy & Commerce Committee released on Wednesday a slimmed-down (see BioCentury, March 15).

The draft includes new proposals, including a requirement that FDA evaluate the use of "clinical experience" rather than randomized clinical trials to support approval of new indications for approved drugs. ...